Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG (2018) Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti--Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial
doi: 10.1159/000086406 29 LangE.JilaniK.ZelenakC.PashamV.BobbalaD.QadriS
This is very crucial given the dynamic nature of therapies involving peptides
10.1094/MPMI.2004.17.1.70 124 Peskan-BerghoferT.ShahollariB.GiongP
[DOI] [PMC free article] [PubMed] [Google Scholar] 52.Szabo A., Kovacs A., Riba J., Djurovic S., Rajnavolgyi E., Frecska E
Supplied as a lyophilised powder in a sealed laboratory vial, third-party HPLC-verified to greater than 99% purity, with a batch-specific Certificate of Analysis available on request